Patients With Severe Eosinophilic Asthma Treated With Mepolizumab: Results From Our Clinical Practice

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.287
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Severe Eosinophilic Asthma and Aspirin-Exacerbated Respiratory Disease Associated to Eosinophilic Gastroenteritis Treated With Mepolizumab: A Case Report

Allergy, Asthma and Clinical Immunology
ImmunologyPulmonaryAllergyRespiratory Medicine
2020English

Mepolizumab for Severe Refractory Eosinophilic Asthma: Evidence to Date and Clinical Potential

Therapeutic Advances in Chronic Disease
Medicine
2016English

Assessment of the Long-Term Safety of Mepolizumab and Durability of Clinical Response in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Prs55 - Cost-Effectiveness of Mepolizumab in Severe Eosinophilic Asthma Patients in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2020English

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics
Pharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy